1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs
  4. >>Emerging Company Profiles

Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

 
• By Ayisha Sharma

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.  

Emerging Company Profile: Iksuda Therapeutics
PermaLink Can Design ADCs That Are Insusceptible To De-Conjugation • Source: Shutterstock
Key Takeaways:

  • Iksuda’s PermaLink technology can design ADCs insusceptible to drug de-conjugation.

  • It has two lead assets targeting CD19 and HER2, respectively, in Phase I development.

  • The firm is in the midst of a minimum $70m series B raise to help reach proof-of-concept.

Iksuda Therapeutics is on mission to design and develop more securely conjugated and efficacious antibody-drug conjugates (ADCs) for the treatment of cancers and is taking a liberated approach to...

The UK firm’s story goes back to 2007 when investor IP Group founded a company called Glythera with two platforms focused respectively on half-life extension and conjugation technology (PermaLink). From...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Emerging Company Profiles

Immusoft Goes For Cell Therapy Plan ‘B’

 
• By Alaric DeArment

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

 
• By Elizabeth Cairns

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 
• By Jessica Merrill

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Seraxis Takes Its Islet Cell Tech Into The Clinic

 
• By Elizabeth Cairns

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

More from Start-Ups & SMEs

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.